-
Company Insights
New![]()
Innovation and Patenting activity of Fujifilm Holdings Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fujifilm Holdings Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FF-10502 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.FF-10502 in Solid Tumor Drug Details:FF-10502 is under development for the treatment of metastatic solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FF-10502 in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FF-10502 in Prostate Cancer Drug Details: FF-10502 is under development for the treatment of metastatic...
-
Company Insights
New![]()
Top Biotechnology Foreign Direct Investment Companies
Top Biotechnology Foreign Direct Investment Companies report analyzes the most active greenfield FDI investors globally (based on number of projects) in the Biotechnology sector between Q1 2019 and Q3 2023. Additionally, the report highlights where these top Biotechnology investors are investing in what type of operations. The report also provides an overview of notable FDI projects from these top investors. The report will be delivered within 2-3 business days of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALNTTRSC-04 in Amyloidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ALNTTRSC-04 in AmyloidosisDrug Details:ALNTTRSC-04 is under development for the treatment of ATTR amyloidosis. It is administered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FF-10101 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.FF-10101 in Relapsed Acute Myeloid Leukemia Drug Details:FF-10101 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FF-10101 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.FF-10101 in Refractory Acute Myeloid Leukemia Drug Details:FF-10101 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RNX-21 in Venous Leg Ulcers (Crural Ulcer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RNX-21 in Venous Leg Ulcers (Crural Ulcer)Drug Details:Molgramostim (RNX-21) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Solid Tumor Drug Details: Gemcitabine hydrochloride (FF-10832) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CYP-001 in Graft Versus Host Disease (GVHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CYP-001 in Graft Versus Host Disease (GVHD) Drug Details: CYP-001 is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.